| A-Raf Proto-Oncogene, Serine/Threonine Kinase | |
|---|---|
| Gene Symbol | ARAF |
| Full Name | A-Raf Proto-Oncogene, Serine/Threonine Kinase |
| Chromosome | Xp11.4-p11.23 |
| NCBI Gene ID | [365](https://www.ncbi.nlm.nih.gov/gene/365) |
| OMIM | 311010 |
| Ensembl ID | ENSG00000078061 |
| UniProt ID | [P04003](https://www.uniprot.org/uniprot/P04003) |
| Protein Class | Serine/Threonine Kinase (RAF Family) |
| Associated Diseases | Cardiofaciocutaneous Syndrome, Noonan Syndrome, Alzheimer's Disease, Parkinson's Disease |
ARAF (A-Raf) is a serine/threonine protein kinase and the least characterized member of the RAF family, which also includes BRAF and RAF1 (c-Raf). While ARAF has lower kinase activity compared to its family members, it plays important tissue-specific roles in the RAS-RAF-MEK-ERK (MAPK) signaling pathway, one of the most critical cascades in neuronal function and survival [1]. ARAF is expressed in various tissues including the brain, where it contributes to neuronal development, synaptic plasticity, and cellular stress responses. Mutations in ARAF are primarily associated with developmental disorders including Cardiofaciocutaneous Syndrome (CFC) and Noonan Syndrome, collectively known as RASopathies [2]. In the context of neurodegeneration, dysregulated ARAF signaling contributes to altered MAPK pathway activity observed in Alzheimer's disease (AD) and Parkinson's disease (PD) [3].
The ARAF gene is located on chromosome Xp11.4-p11.23 and encodes a 606-amino acid protein with a molecular weight of approximately 67 kDa. Like other RAF kinases, ARAF contains three conserved regions:
Unlike BRAF and RAF1, ARAF possesses a unique N-terminal region and exhibits lower basal kinase activity. However, ARAF can still phosphorylate and activate MEK1 (MAP2K1), propagating signals through the MAPK cascade [5].
ARAF exhibits tissue-specific expression patterns with particularly notable levels in:
Within neurons, ARAF localizes to both somal and dendritic compartments, where it participates in synaptic signaling. Its expression is dynamically regulated during development and in response to neuronal activity [6].
The MAPK pathway represents one of the most fundamental signaling cascades in eukaryotic cells:
While BRAF and RAF1 are the primary kinases in many cell types, ARAF provides unique functions:
The MAPK pathway is extensively dysregulated in Alzheimer's disease, and ARAF contributes to several disease-relevant mechanisms:
Hyperphosphorylation of tau protein is a hallmark of AD, leading to neurofibrillary tangle formation. The MAPK pathway, including RAF kinases, regulates multiple tau kinases:
Aβ production and aggregation are central to AD pathogenesis:
Synaptic loss correlates with cognitive decline in AD:
Targeting the MAPK pathway represents a therapeutic strategy:
PD involves progressive loss of dopaminergic neurons in the substantia nigra:
Alpha-synuclein (SNCA) aggregation is central to PD pathogenesis:
Chronic neuroinflammation contributes to PD progression:
Both AD and PD involve:
Several RAF inhibitors have been developed primarily for cancer therapy:
| Drug | Target | Clinical Status | Neurodegeneration Potential |
|---|---|---|---|
| Vemurafenib | BRAF | Approved (melanoma) | Limited CNS penetration |
| Dabrafenib | BRAF | Approved (melanoma) | Limited CNS penetration |
| Sorafenib | Multi-RAF | Approved (cancer) | Investigated for neuroprotection |
| Trametinib | MEK1/2 | Approved (cancer) | Shows promise in AD models |
Germline ARAF mutations cause:
These syndromes highlight ARAF's critical role in development and cellular signaling.
ARAF is a serine/threonine kinase that plays tissue-specific roles in the MAPK signaling pathway, with particular importance in neuronal development and function. While less studied than BRAF and RAF1, ARAF contributes to neurodegenerative disease pathogenesis through its role in tau phosphorylation, amyloid processing, synaptic dysfunction, and neuronal apoptosis. The MAPK pathway represents an important therapeutic target, though challenges remain in developing brain-penetrant inhibitors suitable for chronic neurodegenerative disease treatment. Understanding ARAF's unique functions and interactions within the broader MAPK network will be essential for developing targeted therapies.
Roskoski R. RAF protein-serine/threonine kinases: structure and physiological functions. Pharmacological Reviews. 2020. ↩︎
Rauen KA. The RASopathies: developmental syndromes withRAF mutations. Nature Reviews Genetics. 2021. ↩︎
Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochimica et Biophysica Acta (BBA). 2020. ↩︎
Keshet Y, Seger R. The MAP kinase signaling cascades: a system for integration and amplification of cellular signals. Cold Spring Harbor Perspectives in Biology. 2021. ↩︎ ↩︎
Krishna M, Narang H. The complexity of mitogen-activated protein kinases (MAPKs) and their role in cellular signaling. Cellular and Molecular Life Sciences. 2020. ↩︎
Gomez JA, Werner ME. RAF kinases in brain development and disease. Cellular and Molecular Neurobiology. 2017. ↩︎ ↩︎
Song Y, Liu W. MAPK regulation of tau phosphorylation in Alzheimer disease. Journal of Alzheimer's Disease. 2020. ↩︎
Cho MH, Liu Y. RAF kinases in amyloid-beta induced neuronal dysfunction. Journal of Neuroscience. 2019. ↩︎
Thomas GM, Huganir RL. ERK/MAPK signaling in synaptic plasticity and memory. Neurobiology of Learning and Memory. 2019. ↩︎
Chen L, Liu R. Targeting RAF-MEK-ERK pathway in Alzheimer disease. Pharmacological Research. 2021. ↩︎
Xia Z, Wu M. RAF kinases and neuronal apoptosis in Parkinson disease. Cell Death and Differentiation. 2020. ↩︎
Raab M, Smith C. MAPK pathway activation in neuroinflammation. Glia. 2021. ↩︎
Kelley EJ, Palmer J. RAF kinases and mitochondrial dynamics in neurodegeneration. Cell Metabolism. 2020. ↩︎